Nurix enrolls first patient in bexobrutideg combination trial

Nurix Therapeutics has begun a Phase 1b/2 trial of bexobrutideg and venetoclax for CLL/SLL, part of its Roche collaboration. The study aims to inform future registration strategies and potential antibody combinations.

Nurix Therapeutics (NRIX) has enrolled the first patient in a Phase 1b/2 study of bexobrutideg combined with venetoclax for chronic lymphocytic leukemia (CLL). The trial, part of a collaboration with Roche, aims to evaluate safety, tolerability, and clinical activity. Data may inform future development strategies for CLL and other B-cell malignancies.

Nurix Therapeutics (NRIX) and Gilead Sciences extended their oncology research collaboration by two years. Nurix will receive a $10M extension fee and could earn up to $1.3B in milestones. Nurix retains co-development and 50/50 profit-sharing options for up to two programs in the U.S.

Nurix Therapeutics (NRIX) shares rose 50% premarket after a $2.3B deal with Roche (RHHBY) to develop blood cancer therapy bexobrutideg. Roche will pay $700M upfront, with potential milestone payments. The drug targets a $41B market, including chronic lymphocytic leukemia.

Nurix said Sanofi began a Phase 1 first-in-human trial of SAR448272/NX-3911, an oral STAT6 degrader, triggering a $10 million milestone payment. Nurix reported it has received about $139 million from its 2019 Sanofi collaboration and remains eligible for about $453 million in further STAT6-related milestones. Sanofi runs the trial, with U.S. co-development and co-promotion options for Nurix.

Nurix Therapeutics (Nasdaq: NRIX) reported fiscal Q2 2026 results and a corporate update. It entered a global Roche collaboration for bexobrutideg (NX-5948) with up to $2.3B total payments, including a $700M upfront. Nurix said EHA data showed CLL/SLL ORR of 83% (PFS 22.1 months) and cash of $443.5M as of May 31, 2026.